This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Malkit Singh, MD; A. J. Kanwar, MD; S. C. Bharija, MD; M. S. Belhaj
Department of Dermatology Faculty of Medicine Al Arab Medical University Benghazi, Libya

Arch Dermatol. 1987;123(10):1279-1280.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Vitiligo constitutes nearly 2% of all skin disorders in Benghazi, Libya.¹ It carries a dire social stigma, and patients are often desperate for treatment. All patients with vitiligo from the eastern parts of Libya are referred to our clinic for management.

In the past, we prescribed trioxsalen, 0.6 to 0.8 mg/kg on alternate days, followed by sun exposure two to three hours later as recommended by Mosher et al.² A recent analysis of data collected from our patients showed that nearly 60% of the patients failed to achieve a satisfactory degree of repigmentation, and some patients discontinued the therapy because of poor response. In the patients who did not respond to alternate-day therapy, it was then decided to administer trioxsalen in the same dosage daily, as recommended by Pasricha (personal communication).

Initially, 20 patients were selected for daily therapy. Of these, 15 patients had lesions . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?